Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Houston Convention Center Reopens Equipped with World’s Only Air Biodefense Filtration System Proven to Instantly “Catch and Kill” 99.999% of Airborne Coronavirus


News Image

The mobile, plug-and-purify Air Biodefence Filtration System eliminates SARS-CoV-2, anthrax spores and other airborne contaminants through a heated filter that does not impact the temperature of the ambient air.

Houston’s GEORGE R. BROWN Convention Center announced they are deploying inventor and CEO Monzer Hourani’s Integrated Viral Protection Air Biodefense Filtration System™ at Avenida Houston.

“The time for action is now, and helping our hometown reopen in record timing with this proven science that kills COVID-19 is so important to me as we use Houston-based research to help lead us out of this crisis and get us back to business,” said Monzer Hourani, inventor, and founder of IVP.

Integrated Viral Protection’s S1 model is an affordable, mobile, plug-and-purify device proven to eliminate SARS-CoV-2 (99.999%), anthrax spores (99.8%) and other airborne contaminants through a heated filter without impacting the temperature of the ambient air. A peer-reviewed study demonstrating how the heated air filtration system has been proven to destroy SARS-CoV-2 and other airborne pathogens on contact was published in Materials Physics Today.

For a video explaining IVP’s novel family of mobile and building-installed Catch and Kill™ air filtration and purification solutions, please click here.

“The pandemic has created a number of challenges, but the Houston First team is committed to finding opportunities for safe and functional solutions that will lead the city and the hospitality industry into recovery,” said Michael Heckman, acting president and CEO of Houston First Corporation. “Discovering new technology, new possibilities and new partnerships will not only keep our community safe but allow our economy to rebound.”

ABOUT INTEGRATED VIRAL PROTECTION (IVP)

“We are excited to partner with Houston First and deploy this one and only technology proven to eliminate airborne COVID-19 instantaneously. The invention by Monzer Hourani and the breakthrough research conducted by the Superconductivity Center of Texas at The University of Houston, Galveston National Laboratory at UTMB and Texas A&M Engineering and Experiment Station is a public health game-changer and will offer a sense of security to breathe with confidence indoors,” said Dr. Garrett Peel, principal at IVP.

The results are independently endorsed by premier researchers including Professor Gang Chen at Massachusetts Institute of Technology (MIT): “Timely work with significant real world implications;” Professor George Crabtree, Director of JCESR at Argonne National Laboratory: “…will effectively serve as a mask for indoor ventilation,” and Professor Paul Chu Founding Director at the Texas Center for Superconductivity at University of Houston (Father of Superconductivity, Nobel Prize Nominee and National Medal of Science Awardee): “…as a much needed single hope in this long depressing pandemic.”

The research team is led by Dr. Zhifeng Ren, Director, Texas Center for Superconductivity at University of Houston and Dr. Luo Yu, along with Dr. Faisal Cheema at University of Houston College of Medicine under the leadership of Dean Steve Spann, Vice Chancellor and Vice President of Research and Technology Transfer, Dr. Amr Elnashai and Chancellor and President Renu Khator, Dr. Slobodan Paessler, Distinguished Chair of Biodefense at Galveston National Laboratory and colleagues including Dr. Johnny Peterson and Dr. William Lawrence, Texas A&M University, Vice Chancellor of Engineering and National Laboratories, Dr. Kathy Banks, Associate Dean for Research, The Texas A&M Experiment Engineering Station, Dr. Joe Elabd and Director, NanoBio Systems Laboratory, Dr. Arum Han and John Sharp, Chancellor of the Texas A&M University System.

The patent-pending BIODEFENSE INDOOR AIR PROTECTION SYSTEM™ is FDA Compliant to Enforcement Policy for Sterilizers, Disinfectant Devices and Air Purifiers During the Coronavirus Disease – 2019 (COVID-19) Public Health Emergency | 21 CFR 880.5045 Medical Recirculation Air Cleaner and 21 CFR 880.6500 Medical UV Air Purifier | Class II Device) and permitted by the FDA to be sold during the Coronavirus disease. For more information on IVP, please visit IVPair.com.

Share article on social media or email:

Progressive Dental Marketing and NDX® nSequence Host Webinar, “The Essentials for Qualifying and Closing Full Arch Cases Amidst the Pandemic”


Bart Knellinger, President and CEO of Progressive Dental Marketing

President and CEO of Progressive Dental Marketing, Bart Knellinger Host Webinar with NDX® nSequence

Whether an implant center specialized in full mouth cases or a practice just starting to offer implant solutions, Progressive Dental Marketing has tailored guidance that is proven to grow single to full arch dental implant production.

Two industry leaders, Progressive Dental Marketing and NDX® nSequence partner to provide a webinar for dentists across the nation amid the COVID-19 crisis. This webinar, “The Essentials for Qualifying and Closing Full Arch Cases Amidst the Pandemic” is complimentary and will be held on Tuesday, August 25, 2020, starting at 8 p.m. EST.

Over the past few months, the dental industry has significant and never-before-seen changes. Progressive Dental Marketing has observed the effects of the coronavirus pandemic on countless communities and dental practices across the country, seeing some practices struggle while others thrive. With some clients currently averaging over 20 full arch dental implant cases each month, Progressive Dental Marketing’s President and CEO Bart Knellinger will offer guidance on how implant dentists, especially those with guided implant technology like nSequence, can do the same.

During the webinar, doctors and their staff will learn the following:


  • How to capitalize on the reduction in competition
  • How to quickly triage leads over the phone and with the treatment coordinator, ensuring time spent by the doctor is with the patients that can pay for treatment
  • How to shorten the treatment planning process to increase the number of full arch sales made each week
  • How to create bundles to show value and convert price shoppers

Progressive Dental Marketing has over a decade of experience partnering with some of the largest dental implant centers in the country. Whether an implant center specialized in full mouth cases or a practice just starting to offer implant solutions, Progressive Dental Marketing has tailored guidance that is proven to grow single to full arch dental implant production.

A full-service dental advertising agency, Progressive Dental Marketing offers award-winning tactics ranging from dental website design and digital marketing to videography and radio advertisements. However, an area they find practices need help with the most is in treatment conversion. As a result, they founded dental continuing education courses like Catalyst and The Closing Institute to unite an entire practice around one goal and close large cases with ease. During the upcoming webinar, Knellinger will review segments of the coursework offered in The Closing Institute, a dental sales training program with hands-on boot camps, one-on-one trainings, and monthly calls designed to turn treatment coordinators into closers.

Those interested in attending this online event can visit https://us02web.zoom.us/webinar/register/WN_c3ziR1j8RKGzQQFEBpQJ_w to register. To schedule a complimentary dental marketing analysis with a practice growth consultant on the Progressive Dental Marketing team call 727-286-6211.

About Progressive Dental Marketing

Progressive Dental Marketing (PDM) is a one-stop consulting firm specializing in marketing and practice growth for dental professionals through individualized marketing campaigns, practice development, a continuing education continuum, advertising and more. PDM has become one of the fastest-growing companies in the industry, due to constant innovation, growth and long-term client retention, and has ranked on the Inc. 5000’s list of fastest-growing private companies in America every year since 2015. The company has partnered with some of the largest dental organizations in the country and continues to offer its full-range of services to dental clinicians around the world. For more information about Progressive Dental Marketing please visit http://www.progressivedentalmarketing.com or call 727-286-6211 to schedule a complimentary dental marketing consultation.

Share article on social media or email:

Flow Chemistry – Efficiency in API manufacturing webinar available on-demand


Raybow Pharmaceutical's newly installed Corning G4 reactor

Raybow Pharmaceutical’s newly installed Corning G4 reactor

“Raybow has multiple continuous flow reactors, the largest of which produced more than 140 tonnes of API in 2019. We are happy to be able to share some of what we have learned.” said Dr. Dirk Hütten who co-presents as well as hosts the webinar.

Hosted by Raybow Pharmaceutical and now available on-demand, viewers will explore the benefits of continuous flow reactions in pharmaceutical API & Intermediate manufacturing. Raybow has a long history in the field with experience in R&D as well as manufacturing.

The webinar “Flow Chemistry – Efficiency in API manufacturing” was recorded on June 24, 2020 and can be viewed on Raybow’s new webinar page.

“Raybow has multiple continuous flow reactors, the largest of which produced more than 140 tonnes of API in 2019. We are happy to be able to share some of what we have learned.” said co-presenter Dirk Hütten.

Our guest, Alessandra Vizza from Corning shared her knowledge of flow chemistry and the multiple benefits it can provide as part of an API & Intermediate manufacturing strategy.

The on-demand webinar includes a Q&A where the presenters answered questions from attendees.

Raybow’s continuous flow reactors are located in manufacturing facilities in Taizhou and Suzhou in China as well as our R&D centers in Taizhou and Hangzhou in China. Raybow has a variety of reactors including Corning G1 and G4 units as well as custom reactors built by our in-house team for the specific needs of clients in the pharmaceutical industry.

Raybow has experienced R&D teams at world class R&D centers in Hangzhou and Taizhou in China as well as Brevard, NC in the United States. These teams regularly work with clients from around the world to help them realize the benefits of flow chemistry while advancing the field.

Raybow Pharmaceutical is a global CDMO with team members and facilities in the United States, Europe and China. Raybow Pharma brings client projects from medchem to commercial launch and has developed client NCE’s that are now blockbuster status (USD$1Bill. in prescription sales). We are motivated to create solutions to solve our client’s chemical development challenges in order to get new life saving and life changing small molecule drugs to market successfully.

Share article on social media or email:

WesternU College of Health Sciences dean takes helm at critical time


WesternU College of Health Sciences Dean Dee Schilling, PhD, PT, FNAP

“Dr. Schilling exhibits the steadfast leadership and commitment to our WesternU mission to produce, in a humanistic tradition, health care professionals and biomedical knowledge that will enhance and extend the quality of life in our communities,” said WesternU President Daniel R. Wilson, MD, PhD.

Western University of Health Sciences has selected Dee Schilling, PhD, PT, FNAP, to serve as dean of the College of Health Sciences (CHS) amid an exciting and critical time of expansion and innovation.

Dr. Schilling joined WesternU in 2007 as chair of the Department of Physical Therapy Education. She previously served as CHS associate dean, and for the past year has served as CHS interim dean. She replaces longtime CHS Dean Stephanie Bowlin, EdD, PA, who was promoted to Founding Chief of Mission Integration at WesternU.

“Dr. Schilling exhibits the steadfast leadership and commitment to our WesternU mission to produce, in a humanistic tradition, health care professionals and biomedical knowledge that will enhance and extend the quality of life in our communities,” said WesternU President Daniel R. Wilson, MD, PhD. “The WesternU College of Health Sciences is poised for growth with expansion in Oregon. Dr. Schilling is the right leader at the right time to expand our mission in service to others.”

The College of Health Sciences has three academic programs: Master of Science in Health Sciences, Master of Science in Physician Assistant (PA) Studies and Doctor of Physical Therapy (DPT). Students are provided with classroom and clinical experiences designed to prepare them to function as competent health care practitioners.

“It is with great pleasure that we announce Dr. Schilling as the new dean of the WesternU College of Health Sciences,” said WesternU Senior Vice President and Provost David Baron, DO, MSEd. “Her dedication to academic excellence and diversity ensures that we continue to foster respect for the uniqueness of humanity while we serve our communities. This is more critical now than ever before as we move through this pandemic.”

CHS provides an academic environment built on Schilling’s platform of CARES, which stands for Collaboration, Accountability, Respect, Excellence and Success.

“We are collaborative. We are accountable for what we do. We will always be respectful. We will strive for excellence at all times and our ultimate outcome is student success,” Schilling said.

CHS will welcome its inaugural class of Doctor of Physical Therapy students to the WesternU Oregon campus in Lebanon, Oregon in Fall 2021. CHS is also adding occupational therapy there. The College is hiring DPT faculty in Lebanon and is receiving high levels of interest from prospective students.

The Master of Science in Health Sciences program converted to a fully online program this Fall.

“I’m excited about the future for the College of Health Sciences,” Schilling said. “We are positioned to make great things happen, building on our strong foundation and our legacy of innovation, excellence and success.”

Dr. Schilling’s permanent dean’s appointment was announced to the University on Aug. 4, 2020.

Share article on social media or email:

Staying Open During Covid19 Is A Mixed Blessing Says Owner of First Aid Global LLC


First aid cabinet sits unused in an empty kitchen

What I miss most about our local businesses was the ability to walk into a restaurant and enjoy some of LA’s fabulous cuisine.

First Aid Global LLC is a medical product supplier in Los Angeles selling to both online customers as well as local businesses like law firms, restaurants, entertainment companies and manufacturing industries across LA County. However, the Coronavirus has shut the local economies down and shifted revenues to mostly online platforms.

“We’ve seen the closing of so many of our local businesses,” says Todd West, CFO of First Aid Global LLC. “Aside from the obvious closings of our movie production industries, I think the one that hurts the most are the restaurants. We had hundreds of restaurant customers and in a city like Los Angeles, that really means a lot. And while our service vans sit idle during this pandemic, our website traffic and sales have increased ten-fold over the last 6 months and that represents the current bulk of our business.”

First Aid Global LLC sells PPE and disinfectants to hospitals, municipalities, nursing homes and most importantly to families looking for their own health protection. Much of their full line of first aid products, tablets in sealed packets, emergency preparedness kits and pandemic supplies can be found online at http://www.firstaidglobal.com.

“I worry that online giants are gobbling up businesses and training Americans to shop online instead of visiting their local merchants,” West continues. “What I miss most about our local businesses was the ability to walk into a restaurant and enjoy some of LA’s fabulous cuisine. It’s a real shame that many of these restaurants may never recover.”

Share article on social media or email:

NeoTract Designates Dr. Robert Jansen as UroLift® Center of Excellence


News Image

“We are pleased to recognize Dr. Robert Jansen as a UroLift Center of Excellence for his commitment to providing consistent care to BPH patients using the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Robert Jansen, M.D., Atlantic Urology Clinics in Myrtle Beach, SC, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Jansen has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are pleased to recognize Dr. Robert Jansen as a UroLift Center of Excellence for his commitment to providing consistent care to BPH patients using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “This achievement has helped many patients experience durable, long- term relief from the burdensome symptoms of BPH while preserving sexual function*1,2.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

ARC Entertainment Company Partners With Exceptional Children’s Foundation (ECF) To Bring A Live Ballet Program To Its Students


News Image

“We are excited to offer the gift of dance to the students who are looking for an outlet to move and motivate through these difficult and unprecedented times,” said Kirsten Bloom Allen, founder of ARC Entertainment Company.

ARC Entertainment Company and Exceptional Children’s Foundation (ECF), an organization that provides the highest quality services for children and adults who are challenged with developmental, learning and emotional disabilities – empowering them to reach their greatest potential, are joining forces to provide monthly live ballet instruction to its students who are learning remotely with an interactive program designed to teach and engage the students of ECF Kayne Eras School throughout the fall semester.

The first class will kick off on Wednesday, August 26, 2020, at 11AM and will be instructed through an exclusive dedicated ECF Zoom virtual meeting room and will include a short class instruction, a live performance from ARC Entertainment Company principals and a Q&A so that students can interact directly with the dancers. The series will continue monthly and will engage students from K-12th grade.

The principal dancers of Arc Entertainment Company Kirsten Bloom Allen, Tigran Sargsyan, Magnus Christofferson have designed an original curriculum that will teach the students but will encourage them to participate during their virtual interactive instruction. Kirsten, Magnus, and Tigran are the Directors of ARC Entertainment Company which is their creative concept for merging dance with rock music, art, and cinema.

“We are excited to offer the gift of dance to the students who are looking for an outlet to move and motivate through these difficult and unprecedented times,” said Kirsten Bloom Allen, founder of ARC Entertainment Company. “With no plans for live performances to return anytime soon, our goal is educate and inform but also provide a bit of fun for those who are stuck at home and need to get their bodies moving.”

“ECF is committed to providing ongoing exceptional education and enrichment for our K-12 students at ECF Kayne Eras School, as we meet the challenges of this current pandemic,” said Scott Bowling, ECF President and CEO. “This partnership provides an exciting opportunity for our students and families, and we are thrilled and grateful to ARC Entertainment Company on their behalf.”

ARC Entertainment Company is based in Southern California. Since March 19, when the stay-at-home orders were mandated the trio has been have been living together under one roof in lockdown for the past 100 days, and counting, where they have been performing live in Kirsten’s backyard daily on Facebook https://www.facebook.com/ARCEntertainmentCompany) and Instagram (https://www.instagram.com/arcentertainmentcompany/ ). They have garnered attention from leading news media as well as the US Military, seniors online at http://www.seniorly.com as well as Noah’s Ark, a low-income housing property in Lakeland, Florida and recently appeared on Joey Fatone’s Facebook live show “What Does Joey Know,” and even received a shout out during the San Diego Mayor’s Daily Briefing reminding residents to tune-in and watch the live stream.

The trio have been featured on several nationally syndicated television shows including “Right This Minute,” “Liquid Lunch on Newsmax,” and “Daytime.” Additionally, they have been featured on several television news programs throughout the US including their hometown market of San Diego, Los Angeles, New York, Chicago, Charlotte, Phoenix, and San Antonio.

ABOUT ARC ENTERTAINMENT COMPANY:

Kirsten, Magnus, and Tigran are the Directors of ARC Entertainment Company which is their creative concept for merging dance with rock music, art, and cinema.

Kirsten Bloom Allen is the Founder and Principal Ballerina of ARC Entertainment Company. Allen’s career included many notable performances at the Kennedy Center in Washington DC and well as performances in China. Kirsten also danced a private ballet performance for former president George H.W. Bush and Barbara Bush. Kirsten has been described as a “beautiful dancer with a sensual style of movement that draws her audience in.” Kirsten is a wife and a mother of two boys.

Magnus Christofferson is the Artistic Director and Principal Male Dancer of ARC Entertainment Company. Magnus is from Denmark and danced with the prestigious Royal Danish Ballet in Copenhagen. Magnus wrote produced and starred in the award-winning film “The Dancer”.

Tigran Sargsyan is the Resident Choreographer and Principal Male Dancer of ARC Entertainment Company. Tigran is from Armenia and has performed throughout Europe and the US as a principal male dancer. Tigran competed at the renowned ballet competition “Prix de Lausanne” and received a scholarship from The Rudolph Nureyev Foundation.

For more information please visit http://www.arcentertainmentcompany.com.

ABOUT Exceptional Children’s Foundation:

Exceptional Children’s Foundation (ECF) provides the highest quality services for children and adults who are challenged with developmental, learning and emotional disabilities – empowering them to reach their greatest potential. Each year, ECF serves more than 5,000 clients and their families at 15 service sites, in residential and community settings throughout Los Angeles County. ECF is the only organization of its kind in California to provide a lifespan of services for children and adults with developmental disabilities. Learn more at ECF.net.

About ECF Kayne Eras School:

ECF’s Kayne Eras School is a nonpublic special education school for students in grades K-12.The school accepts referrals from local school districts and charter school. Most Kayne Eras School students have eligibilities including emotional disturbance, autism, intellectual disability, other health impairment and specific learning disability. Kayne Eras School offers services to address these challenges, including: language, speech and occupational therapies; individual and group counseling; and a robust arts education and enrichment program. Visit at KayneErasSchool.org.

Share article on social media or email:



Monica G. Coleman Invited to Join Atlanta Business Chronicle Leadership Trust


Monica G. Coleman

I am thrilled to be among such innovative business leaders and hope to actively contribute to this dynamic community,” said Coleman. “We look forward to providing insight and expertise around niche marketing strategies, which are crucial to success in the ever-evolving business landscape.

Monica G. Coleman, Founder & President of M320 Consulting, has been invited to join Atlanta Business Chronicle Leadership Trust, an exclusive community for influential business leaders, executives and entrepreneurs in the Atlanta area.

Monica was chosen for membership by the Atlanta Business Chronicle Leadership Trust Selection Committee due to her experience, leadership and influence in the local business landscape and beyond. Monica has over 15 years of experience developing multicultural marketing initiatives and consumer activations, working with an array of clients that have included: PepsiCo, Flawless By Gabrielle Union, Coca-Cola United, The National Black MBA Association, The City of Atlanta and many others.

“Atlanta’s thriving business community is powered by leaders like Monica,” said David Rubinger, President and Publisher of Atlanta Business Chronicle. “We’re honored to be creating a space where the region’s business influencers come together to increase their impact on the community, build their businesses and connect with and strengthen one another.”

As an invited member, Monica will contribute articles to the Atlanta Business Chronicle website and participate alongside fellow members in Expert Panels. She will connect and collaborate with a vetted network of local leaders in a members-only directory and a private forum on the group’s mobile app. Monica will also benefit from leadership and business coaching, an Executive Profile on the Atlanta Business Chronicle website, select partner discounts and services and ongoing support from the community’s concierge team.

“I am thrilled to be among such innovative business leaders and hope to actively contribute to this dynamic community,” said Coleman. “We look forward to providing insight and expertise around niche marketing strategies, which are crucial to success in the ever-evolving business landscape.”

The Atlanta Business Chronicle Leadership Trust team is honored to welcome Monica to the community and looks forward to helping her elevate her personal brand, strengthen her circle of trusted advisors and position her to further impact the Atlanta business community and beyond.

About Business Journals Leadership Trust

Atlanta Business Chronicle Leadership Trust is a part of Business Journals Leadership Trust — a collective of invitation-only networks of influential business leaders, executives and entrepreneurs in your community. Membership is based on an application and selection committee review. Benefits include private online forums, the ability to publish insights on bizjournals.com, business and executive coaching and a dedicated concierge team. To learn more and find out if you qualify, visit trust.bizjournals.com.

About M320 Consulting

M320 Consulting is a full-service multicultural marketing firm with experience in the entertainment, consumer products and non-profit sectors. The firm utilizes creative engagement strategies that leverage marketing, public relations, events, social media and influencers to successfully reach consumers in ways that are organic, innovative and fresh. M320 Consulting has worked with an array of brands, which have included: The City of Atlanta, Coca-Cola United, Flawless By Gabrielle Union, The National Black MBA Association, Burger King, PepsiCo, Home Depot and many others. For more information about M320 Consulting, please visit http://www.m320consultinggroup.com.

Share article on social media or email:

Houston Convention Center Reopens Equipped with World’s Only Air Biodefence Filtration System Proven to Instantly “Catch and Kill” 99.999% of Airborne Coronavirus


News Image

The mobile, plug-and-purify Air Biodefence Filtration System eliminates SARS-CoV-2, anthrax spores and other airborne contaminants through a heated filter that does not impact the temperature of the ambient air.

Houston’s GEORGE R. BROWN Convention Center announced they are deploying inventor and CEO Monzer Hourani’s Integrated Viral Protection Air Biodefence Filtration System™ at Avenida Houston.

“The time for action is now, and helping our hometown reopen in record timing with this proven science that kills COVID-19 is so important to me as we use Houston-based research to help lead us out of this crisis and get us back to business,” said Monzer Hourani, inventor, and founder of IVP.

Integrated Viral Protection’s S1 model is an affordable, mobile, plug-and-purify device proven to eliminate SARS-CoV-2 (99.999%), anthrax spores (99.8%) and other airborne contaminants through a heated filter without impacting the temperature of the ambient air. A peer-reviewed study demonstrating how the heated air filtration system has been proven to destroy SARS-CoV-2 and other airborne pathogens on contact was published in Materials Physics Today.

For a video explaining IVP’s novel family of mobile and building-installed Catch and Kill™ air filtration and purification solutions, please click here.

“The pandemic has created a number of challenges, but the Houston First team is committed to finding opportunities for safe and functional solutions that will lead the city and the hospitality industry into recovery,” said Michael Heckman, acting president and CEO of Houston First Corporation. “Discovering new technology, new possibilities and new partnerships will not only keep our community safe but allow our economy to rebound.”

ABOUT INTEGRATED VIRAL PROTECTION (IVP)

“We are excited to partner with Houston First and deploy this one and only technology proven to eliminate airborne COVID-19 instantaneously. The invention by Monzer Hourani and the breakthrough research conducted by the Superconductivity Center of Texas at The University of Houston, Galveston National Laboratory at UTMB and Texas A&M Engineering and Experiment Station is a public health game-changer and will offer a sense of security to breathe with confidence indoors,” said Dr. Garrett Peel, principal at IVP.

The results are independently endorsed by premier researchers including Professor Gang Chen at Massachusetts Institute of Technology (MIT): “Timely work with significant real world implications;” Professor George Crabtree, Director of JCESR at Argonne National Laboratory: “…will effectively serve as a mask for indoor ventilation,” and Professor Paul Chu Founding Director at the Texas Center for Superconductivity at University of Houston (Father of Superconductivity, Nobel Prize Nominee and National Medal of Science Awardee): “…as a much needed single hope in this long depressing pandemic.”

The research team is led by Dr. Zhifeng Ren, Director, Texas Center for Superconductivity at University of Houston and Dr. Luo Yu, along with Dr. Faisal Cheema at University of Houston College of Medicine under the leadership of Dean Steve Spann, Vice Chancellor and Vice President of Research and Technology Transfer, Dr. Amr Elnashai and Chancellor and President Renu Khator, Dr. Slobodan Paessler, Distinguished Chair of Biodefense at Galveston National Laboratory and colleagues including Dr. Johnny Peterson and Dr. William Lawrence, Texas A&M University, Vice Chancellor of Engineering and National Laboratories, Dr. Kathy Banks, Associate Dean for Research, The Texas A&M Experiment Engineering Station, Dr. Joe Elabd and Director, NanoBio Systems Laboratory, Dr. Arum Han and John Sharp, Chancellor of the Texas A&M University System.

The patent-pending BIODEFENSE INDOOR AIR PROTECTION SYSTEM™ is FDA Compliant to Enforcement Policy for Sterilizers, Disinfectant Devices and Air Purifiers During the Coronavirus Disease – 2019 (COVID-19) Public Health Emergency | 21 CFR 880.5045 Medical Recirculation Air Cleaner and 21 CFR 880.6500 Medical UV Air Purifier | Class II Device) and permitted by the FDA to be sold during the Coronavirus disease. For more information on IVP, please visit IVPair.com.

Share article on social media or email:

Mount Sinai Researchers Discover Immune Predictors of COVID-19 Cases that Fare the Worst


Mount Sinai scientists have identified two markers of inflammation that reliably predict the severity of COVID-19 cases and likelihood of survival, providing a foundation for a diagnostic platform and therapeutic targets, according to a study published in Nature Medicine in August.

The researchers studied four proteins known as cytokines that circulate in blood and are commonly associated with infections, and found that two of them, called IL-6 and TNF-α, were able to predict which patients were likely to develop more severe forms of COVID-19 and die. The scientists established that the levels of IL-6 and TNF-α in serum, when measured at admission to the hospital, were elevated in patients who fared the worst, a finding that was independent of the patients’ other underlying medical conditions, of demographics such as age and sex, and of other standard clinical biomarkers of disease severity such as low blood oxygen saturation and common markers related to inflammation, iron levels, and blood clotting issues.

This study suggests that these cytokines should be monitored in the treatment of COVID-19 patients to help select those who should enter clinical trials and receive specific drugs that can target them, the researchers say.

“We propose that serum IL-6 and TNF-α levels should be considered in the management and treatment of COVID-19 patients to stratify prospective clinical trials, guide resource allocation, and inform therapeutic options,” said lead researcher Sacha Gnjatic, PhD, Associate Director of the Human Immune Monitoring Center at Mount Sinai; Associate Professor of Medicine, Oncological Sciences and Pathology, at the Icahn School of Medicine at Mount Sinai; and a member of the Precision Immunology Institute and The Tisch Cancer Institute at Mount Sinai. “We also propose that patients with high IL-6 and TNF-α levels should be assessed for combinatorial blockade of pathogenic inflammation in this disease. Drugs blocking these cytokines are either FDA-approved or in clinical trials.”

When the pandemic began, Mount Sinai scientists promptly implemented a rapid test to measure the levels of four cytokines associated with pathogenic inflammation, which were suspected to cause severity in COVID-19 patients. In just one month, cytokine blood levels were tested in 1,484 patients upon admission to Mount Sinai Health System’s hospitals, and patients were followed for up to 41 days.

Thanks to an emergency authorization from the New York State Department of Health, the test was allowed to be placed in the hospital’s electronic medical record system where doctors order standard blood tests and medicines for patients, allowing for the rapid collection of a large amount of samples. Results were available in three hours, leading researchers to believe it could be implemented in a clinical setting to stratify patients and determine treatments in almost real time.

The results from the tests showed that the risk of death in patients with elevated IL-6 or TNF-α was twofold or higher, even when considering other known risk factors. Scientists then validated their predictive model using samples from an additional cohort of 231 hospitalized COVID-19 patients.

The researchers looked at how various treatments attempted in a subset of these patients affected the cytokines they measured. They found that treatments recently found to benefit COVID-19 patients, such as the antiviral remdesivir or the corticosteroid dexamethasone, could lower the levels of the cytokines.

Based on these results, scientists propose that monitoring COVID-19 patients for these cytokines can help determine their prognosis, and that any treatment should be potentially administered in the context of cytokine measurements, since it affects outcome.

The researchers propose that these findings also call for the use of drugs targeting IL-6 and TNF-α by themselves or combined at the same time, to be tested for their potential benefit based on elevated starting levels.

Monitoring the levels of IL-6 and TNF-a before and during experimental treatments such as anti-cytokine antibodies or corticosteroids will be useful to establish a predictive and prognostic value for these potential biomarkers.

Researchers performing this work were supported by grants U24 CA224319, U01 DK124165, P01 CA190174, and the fast-grant fund. The Human Immune Monitoring Center and the Institute for Healthcare Delivery Science received support from Cancer Center P30 grant CA196521.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email: